ArticleBMC bioinformatics2024
MFSynDCP: multi-source feature collaborative interactive learning for drug combination synergy prediction.
Article in BMC bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Learning drug synergy through environment-conditioned feature modulation.Bioinformatics (Oxford, England) · 2026Article
- PDTSyn: a parameter-decomposed transformer for domain-generalized cell line-aware drug synergy prediction.Briefings in bioinformatics · 2026Article
- TensoGraph: a tensor-transformer framework for global-local drug synergy prediction on heterogeneous graphs.Briefings in bioinformatics · 2026Article
- GATRSyn: Advancing Anticancer Drug Synergy Prediction Through Graph Attention Networks and Transformer-based Feature Re-embedding.Interdisciplinary sciences, computational life sciences · 2026Article
- Systematic modeling predicts synergistic and safe drug combinations for parasitic diseases.PLoS neglected tropical diseases · 2026Article
- MetaComb: a meta-learning framework for drug combination response prediction from cell lines to patients.Frontiers in genetics · 2026Article
- A review of deep learning approaches for drug synergy prediction in cancer.npj drug discovery · 2025Review
- Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework.International journal of molecular sciences · 2025Review
- BridgeSyn: a bridging fusion framework for drug combination synergy prediction.Briefings in bioinformatics · 2025Article
- Accurate prediction of synergistic drug combination using a multi-source information fusion framework.BMC biology · 2025Article
- Towards interpretable drug interaction predictionPeerJ. Computer science · 2025Article
- Improving synergistic drug combination prediction with signature-based gene expression features in oncology.Frontiers in pharmacology · 2025Article
- DeepBP: Ensemble deep learning strategy for bioactive peptide prediction.BMC bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Drug combination therapy is generally more effective than monotherapy in the field of cancer treatment. However, screening for effective synergistic combinations from a wide range of drug combinations is particularly important given the increase in the number of available drug classes and potential drug-drug interactions. Existing methods for predicting the synergistic effects of drug combinations primarily focus on extracting structural features of drug molecules and cell lines, but neglect the interaction mechanisms between cell lines and drug combinations. Consequently, there is a deficiency in comprehensive understanding of the synergistic effects of drug combinations. To address this issue, we propose a drug combination synergy prediction model based on multi-source feature interaction learning, named MFSynDCP, aiming to predict the synergistic effects of anti-tumor drug combinations. This model includes a graph aggregation module with an adaptive attention mechanism for learning drug interactions and a multi-source feature interaction learning controller for managing information transfer between different data sources, accommodating both drug and cell line features. Comparative studies with benchmark datasets demonstrate MFSynDCP's superiority over existing methods. Additionally, its adaptive attention mechanism graph aggregation module identifies drug chemical substructures crucial to the synergy mechanism. Overall, MFSynDCP is a robust tool for predicting synergistic drug combinations. The source code is available from GitHub at https://github.com/kkioplkg/MFSynDCP .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.